Metabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like peptide-1 receptor agonists (GLP-1s), according to one of the largest and most comprehensive real-world comparisons of the two treatments. The findings were presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting (ASMBS2026).
This article was originally published on MedicalXpress.com

